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Summary 
An Epstein-Barr virus-encoded protein, LMP2, blocks 
the effects of surface immunoglobulin (slg) cross-linking 
on calcium mobilization and on lytic reactivation of 
EBV in latently infected and growth-transformed pri- 
mary human B lymphocytes. In wild-type EBV-trans- 
formed cells, LMP2 is constitutively tyrosine phosphory- 
lated and is associated with Lyn and Syk protein-tyrosine 
kinases (PTKs). Baseline Lyn PTK activity is substan- 
tially reduced, and slg cross-linking fails to activate Lyn, 
Syk, PI3-K, PLCy2, Vav, Shc, and MAPK. Syk, PI3-K, 
PLCy2, and Vav are constitutively tyrosine phosphory- 
lated, and their tyrosine phosphorylation does not 
change following slg cross-linking. In contrast, cross- 
linking slg on cells transformed by LMP2 null mutant 
EBV recombinants triggers the same protein tyrosine 
kinase cascade as in noninfected B lymphocytes. These 
data are consistent with a model in which LMP2 is a 
constitutive dominant negative modulator of slg recep- 
tor signaling through its effects on Lyn, Syk, or regula- 
tors of these kinases. 
Introduction 
Epstein-Barr virus (EBV) is an important human pathogen 
that causes infectious mononucleosis and B-lymphopro- 
liferative disorders in immunocompromised hosts (for re- 
view see Miller, 1990; Liebowitz and Kieff, 1993). Primary 
infection begins in the oropharyngeal epithelium, which 
is fully permissive for virus replication. B lymphocytes be- 
come latently infected, resulting in cell growth transforma- 
tion. Long-lived latently infected B lymphocytes circulate 
to lymph nodes, bone marrow, and epithelial surfaces. 
Periodic reactivations of lytic infection in lymphocytes traf- 
ficking near the oropharyngeal epithelium results in epi- 
thelial cell infection and release of new virus, completing 
the virus life cycle. 
Latent EBV infection in B lymphocytes involves the ex- 
pression of a small subset of EBV genes (for review see 
Miller, 1990; Liebowitz and Kieff, 1993). Several are essen- 
tial for latent infection or cell growth transformation of hu- 
man B lymphocytes in vitro, while others are dispensable 
and are presumed to provide essential function only in in 
vivo infection (Hammerschmidt and Sugden, 1989; Cohen 
et al., 1989; Mannick et al., 1991; Swaminathan et al., 
1991; Marchini et al., 1991; Tomkinson and Kieff, 1992; 
Tomkinson et al., 1993; Longnecker et al., 1993b; Kaye 
et al., 1993; Robertson et al., 1994; Kim and Yates, 1993). 
The subject of the experiments described here is LMP2, 
an EBV gene that appears to be important for EBV infec- 
tion in vivo, but not in vitro. EBV recombinants with specifi- 
cally inactivated LMP2 genes are fully competent for latent 
infection and cell growth transformation in vitro (Long- 
necker et al., 1992, 1993a, 1993b; Kim and Yates, 1993). 
Despite its dispensability for latent growth-transforming 
infection in vitro, and cytotoxic T cell selection against its 
expression in natural infection (Murray et al., 1992), LMP2 
is expressed in latently infected B lymphocytes and naso- 
pharyngeal carcinoma tumors in vivo (Qu and Rowe, 1992; 
Brooks et al., 1992; Busson et al., 1992). 
Recent experiments have demonstrated that LMP2 pre- 
vents lytic reactivation in response to surface immunoglob- 
ulin (slg) cross-linking (Miller et al., 1994). Cross-linking of 
slg efficiently activates a switch to lytic EBV gene expres- 
sion in an unusual latently EBV-infected Burkitt lymphoma 
(BL) cell line (Tovey et al., 1978; Takada, 1984; Takada 
and Ono, 1989; Daibata et al., 1990), in which LMP2 is 
not expressed. Engagement of slg on these cells induces 
expression of the immediate-early tic gene BZLF1, which 
transactivates other lytic cycle viral genes (Kenney et al., 
1989; Rooney et al., 1989; Sinclair et al., 1991). In a pro- 
spective study comparing cell lines transformed by LMP2 
null mutant EBV recombinants with cell lines transformed 
by wild-type EBV recombinants, only the LMP2 mutant 
recombinant-infected cells had a rapid increase in intracel- 
lular free calcium and activated lytic gene expression after 
slg cross-linking, despite similar levels of slg expression 
on these cells (Miller et al., 1994). This effect of LMP2 on 
preventing reactivation would be important in vivo, so that 
fortuitous lytic reactivations would not occur in circulating 
B lymphocytes, since that would result in immune destruc- 
tion of the latent reservoir of virus. A corollary of this hy- 
pothesis is that trafficking near or through epithelium re- 
sults in engagement of other types of receptors that can 
bypass the LMP2 blockade, and induce lytic reactivation 
at sites where the virus can complete its life cycle. 
The experiments reported here investigate the mecha- 
nisms by which LMP2 blocks slg-mediated lytic reactiva- 
tion without affecting cell growth. LMP2 is a tyrosine-phos- 
phorylated integral membrane protein that colocalizes in 
plasma membrane patches with the majority of antiphos- 
photyrosine (APT) reactivity in latently EBV-infected cells 
(Longnecker et al., 1991). The 119 aa N-terminal cyto- 
plasmic and first two of twelve transmembrane domains 
are sufficient for interaction with B lymphocyte protein- 
tyrosine kinases (PTKs), including members of the Src 
PTK family, and a 70 kDa tyrosine-phosphorylated protein 
Immunity 
156 
A 
200- 
97.4- 
s9,- 
46- 
30- 
B 
EBV- 
- 30"1' 5 '10 '  
i 
,iiiii i ,' ii ',' ii ~ ii, i!, i,~ i " 
EBV+ EBV+ 
LMP2- LMP2+ 
97.4- 
69- 
46- 
30" 1' 5' 10' -30"1 '  5'10' 
EBV+ EBV+ EBV+ EBV+ 
LMP2- LMP2+ LMP2- LMP2+ 
1' 10' 1' 10' 1' 10' - 1' 10' 
APT i.p. 
APT blot 
Figure 1. Changes in Tyrosine Phosphoryla- 
tion Pattern Following Cross-Linking slg on 
EBV, EBV÷LMP2 -, and EBV÷LMP2 + Cells 
(A) Cells were either untreated (minus) or 
treated at 5 x 10 ~ cells/ml with anti- 
immunoglobulin antibody for the indicated 
times (30 s, 1 min, 5 min, 10 rain) and lysed in 
NP40 1 x lysis buffer. Cleared lysates from 5 x 
107 cells were immunoprecipitated (i.p.) with 
monoclonal APT, followed by formalin-fixed 
Staphylococcus aureus, and immunoprecipi- 
tated proteins were fractionated by 9% SDS- 
PAGE, transferred to nitrocellulose, probed 
with rabbit APT antibody (blot), and detected 
by 12~l-labeled protein A. 
(B) Immunoprecipitated LMP2 is constitutively 
tyrosine phosphorylated in EBV÷LMP2 ÷ cells. 
Cellular lysates were immunoprecipitated with 
either rabbit anti-LMP2 or APT antibodies, as 
indicated in the figure. Size standards areindi- 
cated in kilodaltons. 
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(Longnecker et al., 1991; Burkhardt et al., 1992). The 
mechanism by which LMP2 confers a dominant negative 
block on slg-mediated effects is likely to be related to these 
properties, since cellular PTKs are involved in slg- 
mediated signal transduction. 
slg is part of a signal-transducing receptor complex that 
includes disulfide-linked heterodimers of Ig~(mbl) and 
Ig~(B29) (for review see DeFranco, 1993; Weiss and Litt- 
man, 1994). The Ig~ and Ig~ cytoplasmic domains interact 
with Src family and Syk PTKs (for review see DeFranco, 
1993; Weiss and Littman, 1994). The cytoplasmic domains 
of these B cell receptor (BCR)-associated proteins include 
the sequences YEEI and YXXL(N)TYXXL, which, once 
phosphorylated, can interact with Src family and Syk 
PTKs, respectively (Songyang et al., 1993; for review see 
DeFranco, 1993; Weiss and Littman, 1994). These motifs 
are in signal transducing components of other immune 
cell receptors (Reth, 1989; Cambier and Campbell, 1992), 
and in the cytoplasmic N-terminal domain of LMP2 (Beau- 
ills et al., 1993; Alber et al., 1993; Miller et ai., 1994). 
Stimulation of the BCR initiates a biochemical cascade 
in which induction of PTK activity is among the earliest 
known events, resulting in the tyrosine phosphorylation 
of a number of cellular proteins (Campbell and Cambier, 
1990; Gold et al., 1990; Brunswick et al., 1991). Syk PTK 
phosphorylates and activates phospholipase C~, (PLC~,), 
which releases inositol 1,4,5-triphosphate (IP3) and diacyl- 
glycerol (DAG), resulting in Ca 2÷ mobilization and protein 
kinase C (PKC) activation (for review see DeFranco, 1993; 
Weiss and Littman, 1994). We now describe the effects 
of LMP2 on processes downstream of slg cross-linking 
by comparing protein tyrosine phosphorylation in pri- 
mary human B lymphocytes transformed by wild-type 
(EBV÷LMP2 +) or LMP2 null mutant (EBV÷LMP2 -) EBV. 
Results 
LMP2 Blocks slg-Activated Protein-Tyrosine 
Phosphorylation in EBV+LMP2 * Infected LCLs 
The effects of slg cross-linking on protein-tyrosine phos- 
phorylation in EBV-negative (EBV-) B lymphoma cells, and 
wild-type EBV-transformed primary human B lympho- 
cytes (EBV+LMP2 + lymphoblastoid cell lines [LCLs]) and 
LMP2 null mutant recombinant EBV-transformed cells 
(EBV+LMP2 - LCLs) matched for slg expression levels, 
were evaluated. Representative data are shown in Figure 
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Figure 2. Time Course of Lyn PTK Activation 
Following slg Cross-Linking on EBV, 
EBV+LMP2 -, and EBV+LMP2 ÷ Cells 
For each cell line, 1 x 107 ceils/ml were stimu- 
lated with anti-immunoglobulin, NP40 cellular 
lysates were prepared, and parallel immuno- 
precipitations and immunoblotting were per- 
formed as indicated next o the relevant panel. 
Immunoprecipitated Lyn from 1 x 106 cells/ 
i.p. were subjected to in vitro immune complex 
kinase assays (invk) for 1 min reactions, ~zp. 
labeled products (auto P) were separated by 
9% SDS-PAGE, and visualized by autoradiog- 
raphy of the dried down gels. Parallel immuno- 
precipitates were performed and immunoblot- 
ted to verify equivalent immunoprecipitation of 
Lyn during the time course (data not shown). 
Size standards are indicated in kilodaltons. 
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1A. Lysates from unstimulated EBV- B lymphoma cells or 
unstimulated EBV÷LMP2 - LCLs had little reactivity with 
APT antibodies. Cross-linking slg on these cell types in- 
duced the rapid tyrosine phosphorylation of many pro- 
teins. In contrast, in unstimulated EBV÷LMP2 ÷ LCLs, pro- 
teins of approximately 54, 72, and 75 kDa were found to 
be constitutively t rosine phosphorylated, and this pattern 
remained relatively unchanged after slg cross-linking. 
The predominant 54 kDa tyrosine-phosphorylated pro- 
tein detected only in EBV+LMP2 + LCLs is identical in size 
to immunoprecipitated LMP2 (Figure 1B). Parallel immu- 
noprecipitation with APT antibodies followed by immu- 
noblotting for LMP2 demonstrated that the 54 kDa tyro- 
sine-phosphorylated protein is LMP2, and that most of 
the LMP2 in unstimulated EBV÷LMP2 + infected cells is 
tyrosine phosphorylated. The phosphorylation of LMP2 
was not affected by anti-immunoglobulin treatment. 
Lyn and Syk PTKs Are Stimulated by slg 
Cross-Linking in EBV+LMP2 - but Not 
EBV+LMP2 ÷ Infected LCLs 
The repertoire of PTK expression in these LCLs was deter- 
mined using kinase-specific antibodies in immune precipi- 
tation, followed by immune complex kinase assays. Lyn, 
Fyn, Lck, Syk, and Btk PTKs were detected in each of 
three EB.V÷LMP2 - and three EBV÷LMP2 + LCLs tested 
(data not shown). Thus, EBV+LMP2 - and EBV÷LMP2 + 
LCLs have similar repertoires of PTKs. 
Stimulation through slg results in increased tyrosine 
phosphorylation of Src family and Syk PTKs, and a con- 
comitant increase in kinase activity (Burkhardt e al., 1991 ; 
Yamanashi et al., 1991, 1992; Hutchcroft et al., 1991, 
1992; Campbell and Sefton, 1992; Law et al., 1994; Saouaf 
et al., 1994). To discern the effect of LMP2, we first identi- 
fied PTK(s) that are activated upon slg cross-linking in the 
EBV+LMP2 - LCLs. Rapid increases in immune complex 
kinase activity of Lyn and Syk occurred following stimula- 
tion with anti-immunoglobulin antibodies, whereas Src, 
Fyn, and Lck activities did not significantly increase above 
that seen in the unstimulated cells (data not shown). There- 
fore, Lyn and Syk may be targets of an LMP2-imposed 
block on slg-induced signal transduction. 
Immunoprecipitation and immunoblotting for the Src 
family PTK member Lyn detected primarily the p56 Lyn 
form and a small amount of the alternatively spliced p53 
Lyn (Yi et al., 1991) in each cell type (Figure 2). The 
EBV÷LMP2 ÷ LCLs had slightly less Lyn protein than either 
EBV- or EBV÷LMP2 - cells. Immunoprecipitation a d im- 
munoblotting for Lyn in a panel of five EBV÷LMP2 and 
five EBV+LMP2 ÷ LCL lines similarly detected slightly less 
Lyn protein in EBV÷LMP2 + LCLs (data not shown). Immu- 
noprecipitated Lyn from each unstimulated cell type was 
found to be moderatively APT reactive (Figure 2). In three 
independent experiments, the APT reactivity increased 
rapidly and transiently following slg cross-linking on EBV- 
and EBV÷LMP2 - LCLs, whereas immunoprecipitated Lyn 
from EBV÷LMP2 ÷ LCLs was unchanged upon slg stimula- 
tion. Immunoprecipitation with APT antibodies and immu- 
noblotting with Lyn-specific antibody yielded similar re- 
sults, although the p53 Lyn was better visualized (Figure 2). 
Lyn in vitro immune complex kinase activity inEBV÷LMP2 - 
LCLs paralleled the rapid transient increase in Lyn tyrosine 
phosphorylation observed following slg stimulation (Fig- 
ure 2). The peak change in Lyn autophosphorylation activ- 
ity was found to be 2- to 3-fold in three independent experi- 
ments. At later timepoints, the enzymatic activity of Lyn 
fell below that of unstimulated cells, as has previously 
been reported (Li et al., 1992; Eiseman and Bolen, 1992). 
Surprisingly, Lyn activity from unstimulated EBV÷LMP2 ÷ 
LCLs was minimal as measured by this assay, and re- 
mained minimal following slg cross-linking (Figure 2). Par- 
allel immunoprecipitations followed by Lyn immunoblot- 
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Figure 3. Time Course of Syk PTK Activation 
Following slg Cross-Linking on EBV, 
EBV+LMP2 -, and EBV÷LMP2 + Cells 
For each cell line, 2 x 107 cells/ml were stimu- 
lated with anti-immunoglobulin, lysates were 
prepared, and immunopreoipitations followed 
by immunoblotting were performed in parallel 
as indicated next o the relevant panel. Immu- 
noprecipitated Syk (5 x 108 cells/i.p.) before 
and after slg cross-linking were subjected to 1 
min in vitro immune complex kinase reactions, 
and a2P-labeled products were separated by 
9% SDS-PAGE and visualized by autoradiog- 
raphy. Parallel immunoprecipitations a d im- 
munoblots for Syk were performed to verify 
equivalent immunoprecipitation of Syk protein 
during the time course (data not shown). Size 
standards are indicated in kilodaltons. 
ting were conducted to ensure equivalent levels of Lyn 
PTK were immunoprecipitated at each timepoint in the in 
vitro kinase assays (data not shown). Lyn from EBV÷LMP2 ÷ 
cells was found to be similarly inactive in immune complex 
kinase assays using exogenous substrates (data not 
shown). 
Changes in p72 Syk tyrosine phosphorylation following 
slg stimulation in EBV-, EBV+LMP2 -, and EBV+LMP2 + 
cells were assayed by immunoprecipitation with Syk- 
specific antibody, and immunoblotting with APT antibod- 
ies (Figure 3). Tyrosine-phosphorylated Syk was barely 
detectable in unstimulated EBV- and EBV÷LMP2 - cells, 
and became rapidly abundant upon cross-linking slg. in 
contrast, in unstimulated EBV÷LMP2 + LCLs Syk was sig- 
nificantly tyrosine phosphorylated and did not change 
upon slg stimulation. These data, consistently observed 
in several independent experiments, suggest that the 
constitutively tyrosine-phosphorylated 72 kDa protein in 
EBV+LMP2 + LCLs (see Figure 1A) is Syk PTK. immunopre- 
cipitation with APT antibodies and immunoblotting for Syk 
yielded similar confirmatory results, indicating that in each 
cell type, changes in tyrosine phosphorylation applied to 
the Syk population as a whole, and not to a small subpopu- 
lation of Syk molecules in each cell type. Syk protein levels 
as determined by immunoprecipitation a d immunoblot- 
ting were similar in all cell types. 
Changes in Syk enzymatic activities were evaluated us- 
ing immune complex kinase assays (Figure 3). Syk auto- 
phosphorylation increased rapidly following slg stimula- 
tion in EBV- and EBV+LMP2 - cells. The peak change in 
Syk autophosphorylation activity was found to be 3- to 
4-fold in four independent experiments. Equivalent levels 
of immunoprecipitated Syk were controlled for by conduct- 
ing parallel Syk immunoprecipitations followed by Syk im- 
munoblotting (data not shown). Surprisingly, despite the 
constitutive levation in Syk tyrosine phosphorylation in 
unstimulated EBV+LMP2 ÷ LCLs, Syk enzymatic activity 
was slightly lower than that observed in EBV+LMP2 - LCLs, 
and was essentially unresponsive to slg cross-linking. Syk 
immunoprecipitation followed by in vitro immune complex 
kinase assay in a panel of five EBV+LMP2 ÷ and five 
EBV+LMP2 - cell lines demonstrated similarly reduced 
baseline Syk autophosphorylation activity (data not shown). 
Similar results were obtained in immune complex kinase 
assays using exogenous phosphorylation substrates (data 
not shown). 
Immunoglobulin Receptor-Associated PTK Activity 
Is Significantly Reduced in EBV+LMP2 ÷ LCLs 
Following slg engagement, increased PTK activities are 
associated with Igc( and Ig13, which become rapidly tyro- 
sine phosphorylated (Burkhardt et al., 1991; Yamanashi 
et al., 1991; Hutchcroft et al., 1992; Law et al., 1994; 
Saouaf et al., 1994; Li et al., 1992). We therefore compared 
slg complex-associated PTK activities in EBV+LMP2 - and 
EBV+LMP2 ÷ LCLs before and after receptor cross-linking. 
Immunoglobulin receptor complexes were immunopre- 
cipitated from digitonin lysates of resting or anti-immu- 
noglobulin-stimulated cells, labeled in immune complex 
protein kinase assays, disrupted, and reimmunoprecipi- 
tated with antibody to either phosphotyrosine, Ig~, Syk, or 
Lyn (Figure 4). Immunoglobulin receptor complexes from 
unstimulated EBV- and EBV+LMP2 - cells showed low lev- 
els of associated PTK activity as measured by 32p incorpo- 
ration into APT and anti-lgl~ reimmunoprecipitates. Follow- 
ing slg cross-linking, significantly more PTK activity was 
associated with these slg complexes, as indicated by the 
dramatic increase in phosphorylation of APT and anti-lgl3 
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Figure 4. PTK Activities Associated with slg Receptor Complexes from EBV, EBV+LMP2 -, and EBV+LMP2 + Cells 
Cells (5 x 108) were either unstimulated (minus) or stimulated (plus) with anti-immunoglobulin antibody for 10 min and were lysed in digitonin 
buffer, slg complexes were immunoprecipitated with rabbit anti-human immunoglobulin antibody and labeled by 5 min in vitro kinase reactions. 
The labeled complexes were then disrupted and reimmunoprecipitated with the indicated antibodies. 32P-labeled proteins were separated by 10% 
SDS-PAGE, and visualized by autoradiography of the dried gels. 
reimmunoprecipitates. The immunoprecipitation of hu- 
man Ig13 (37 kDa glycoprotein) coprecipitates human Ig(~ 
(47 kDa glycoprotein), owing to disulfide linkage between 
these molecules (Mason et al., 1991; Clark et al., 1992; 
Hombach et al., 1990). Immunoglobulin-associated Lyn 
activity changed slightly following receptor cross-linking 
only in the EBV- cells, whereas immunoglobulin-asso- 
ciated Syk activity significantly increased in both EBV- 
and EBV+LMP2 - cells. 
In unstimulated EBV+LMP2 + cells, less PTK activity was 
associated with slg receptor complexes (Figure 4). There 
was significantly less change in slg-associated kinase ac- 
tivity following receptor stimulation. This is most obviously 
demonstrated by the Ig13 and Syk reimmunoprecipitates 
(Figure 4). Thus, immunoglobulin receptor complexes 
from EBV+LMP2 + infected cells are associated with less 
PTK activity before and after slg cross-linking. 
LMP2 Associates with Lyn and Syk PTKs 
Similar to slg receptor complexes, LMP2 has been shown 
to become tyrosine phosphorylated in immune complex 
kinase assays, and to associate with Lyn and Fyn PTKs 
(Longnecker et al., 1991 ; Burkhardt et al., 1992). To deter- 
mine whether LMP2 also associates with Syk, LMP2 com- 
plexes from unstimulated EBV+LMP2 + and EBV+LMP2 - 
control cells were immunoprecipitated from digitonin lysates, 
labeled by immune complex kinase reactions, dissociated, 
and reimmunoprecipitated with antibody to phosphotyro- 
sine, LMP2, or Syk (Figure 5). 32P-labeled Syk was readily 
detected in LMP2 complexes from EBV+LMP2 ÷ lysate. 
Thus, LMP2 constitutively associates with the same PTK 
activities as activated slg receptor complexes. 
PI3-K, Vav, and PLCy2 Are Unresponsive to slg 
Stimulation in EBV+LMP2 + LCLs 
slg cross-linking induces tyrosine phosphorylation of the 
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Figure 5. PTK Activities Associated with LMP2A Complexes from 
EBV+LMP2 + Cells 
Cell lysates were prepared in digitonin lysis buffer and immunoprecipi- 
tated with rabbit anti-LMP2 antibody. The immune complexes were 
subjected to 5 min in vitro kinase reactions, labeled complexes w r  
then disrupted, and lysates were reimmunoprecipitated as indicated 
in the figure. ~2P-labeled proteins were separated by 10% SDS-PAGE 
and visualized by autoradiography. 
p85 subunit of phosphatidylinositol-3' kinase (PI3-K), and 
its association with both the PI3-K 110 kDa subunit and Lyn 
PTK (Yamanashi et al., 1992; Gold et al., 1992; Pleiman 
et al., 1994). Unstimulated EBV- and EBV+LMP2 - cells 
displayed low levels of tyrosine-phosphorylated p85, 
which rapidly increased following slg cross-linking (Figure 
6A). Protein(s) of 95-125 kDa coimmunoprecipitated with 
p85 from unstimulated EBV- and EBV+LMP2 - cells, and 
these dramatically increased following slg stimulation. Fi- 
nally, both forms of Lyn coimmunoprecipitated with tyro- 
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Figure 6. Tyrosine Phosphorylation of Down- 
stream PTK Substrates Following slg Cross- 
Linking on EBVL EBV+LMP2L and 
EBV÷LMP2 + Cells 
For each cell line, 1 x 10 ~ cells/ml were stimu- 
lated with anti-immunoglobulin antibody and 
NP40 cellular lysates were immunoprecipi- 
tated with either anti-p85 (A), anti-Vav (B), or 
anti-PLCy2 (C). Parallel immunoprecipitates 
were resolved by 90/0 SDS-PAGE, and were 
subjected to immu noblotting as indicated in the 
figures. 
B EBV- EBV+ EBV+ 
LMP2- LMP2+ 
- 30"1 '  5' 10' 30"1 '  5' 10' . 30"1 '  5' 10' 
97.4- , m ~ ~  <Vav> Vav i.p. 
+ 
69- Vav blot 
97.4- ~ ~  <Vav> ~ Vav i.p. 
69- APT blot 
C 
200- 
97.4- 
200- 
97.4- 
EBV- EBV+ EBV+ 
LMP2- LMP2+ 
1' 10' - 1' 10' - 1' 10' 
PLC~/2 i.p. 
PLC~/2 blot 
PLCy2 i.p. 
< I, 
APT blot 
sine-phosphorylated p85. In contrast, p85 in unstimulated 
EBV+LMP2 ÷ cells was more tyrosine phosphorylated as 
compared with the LMP2-deficient cells, and did not change 
following slg cross-linking (Figure 6A). The 95-125 kDa 
tyrosine-phosphorylated protein(s) were constitutively as- 
sociated with p85, whereas coimmunoprecipitating Lyn 
was barely detectable. Expression of p85 was similar in 
all three cell types as determined by parallel p85 immuno- 
precipitation followed by p85 immunoblotting. 
p95 Vav is also rapidly and transiently phosphorylated 
on tyrosine after cross-linking antigen receptors on T or 
B cells (Bustelo and Barbacid, 1992; Bustelo et al., 1992; 
Margolis et al., 1992). Vav was weakly tyrosine phosphory- 
lated in unstimulated EBV- and EBV+LMP2 - cells, but 
phosphorylation rapidly increased following slg stimula- 
tion (Figure 6B). p95 Vav from unstimulated EBV+LMP2 ÷ 
LCLs was increased in constitutive tyrosine phosphoryla- 
tion, and was unchanged following slg cross-linking. Con- 
trol immunoprecipitations and immunoblotting for p95 Vav 
demonstrated similar levels of p95 Vav expression in all 
three cell types. 
The predominant PLCy isoform expressed in human B 
lymphocytes is PLCy2, which is rapidly tyrosine phosphor- 
ylated following slg cross-linking (Coggeshall et al., 1992). 
PLCy2 was not tyrosine phosphorylated in unstimulated 
EBV- and EBV+LMP2 - cells, but became rapidly and tran- 
siently tyrosine phosphorylated following slg cross-linking 
(Figure 6C). Similar to p85 PI3-K and p95 Vav, PLCy2 
is constitutively tyrosine phosphorylated in unstimulated 
EBV+LMP2 ÷ cells, and was unchanged following slg cross- 
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Figure 7. Tyrosine Phosphoryiation of Shc, 
and its Subsequent Association with Grb2, in 
response to slg Cross-Linking on EBV-, 
EBV÷LMP2, and EBV+LMP2 + Cells 
For each cell line, 1 x 107 cells/ml were stimu- 
lated with anti-immunogiobulin antibody, NP40 
cellular lysates were prepared and immunopre- 
cipitated with anti-Shc or anti-Grb2 in parallel, 
were resolved by 10% SDS-PAGE, and were 
subjected to immu noblotting as indicated in the 
figure. 
linking. The abundance of PLC~,2 was similar in all three 
cell types. PLC~,I isoform was also present in these cell 
lines, but was not tyrosine phosphorylated before or after 
slg stimulation in any of these three cell types (data not 
shown). 
Shc-Mediated Activation of the Ras Pathway Does 
not Occur in Response to slg Stimulation 
of EBV÷LMP2 + LCLs 
slg cross-linking induces tyrosine phosphorylation of Shc 
proteins, resulting in their association with the SH2 do- 
main-containing adaptor protein Grb2 (Saxton et al., 1994; 
Smit et al., 1994). The Shc-Grb2 complex has been impli- 
cated in coupling a variety of receptors to p21 Ras activa- 
tion (Rozakis-Adcock et al., 1992; Egan et al., 1993; Buday 
and Downward, 1993; Gale et al., 1993; Li et al., 1993; 
Ravichandran et al., 1993). Downstream components of 
the Ras pathway (Ras, Gap, Raf-1, MEK, and MAPK) are 
activated following slg stimulation (Casillas et al., 1991; 
Tamaki et al., 1992; Harwood and Cambier, 1993; Gold 
et al., 1993; Tordai et al., 1994). 
Shc was not tyrosine phosphorylated in unstimulated 
EBV and EBV+LMP2 - cells, but became rapidly tyrosine 
phosphorylated on the 48 and 52 kDa forms of Shc follow- 
ing slg cross-linking (Figure 7). Grb2 coimmunoprecipi- 
tated with Shc only at times when Shc was tyrosine phos- 
phorylated. Tyrosine phosphorylation of MAPK was also 
induced upon slg cross-linking on EBV- and EBV÷LMP2 
cells (data not shown). While comparable levels of Shc 
were detected in EBV+LMP2 ÷ cells, no tyrosine-phesphor- 
ylated Shc was observed before or after slg stimulation. 
Consistent with the absence of tyrosine-phosphorylated 
Shc, Grb2 did not coimmunoprecipitate with Shc from 
these cells (Figure 7), and MAPK was not inducibly tyro- 
sine phosphorylated following slg cross-linking (data not 
shown). Therefore, LMP2 expression does not constitu- 
tively activate the Shc-Grb2-mediated Ras pathway, and 
this pathway is not activated in response to slg cross- 
linking in EBV+LMP2 + cells. 
Discussion 
These experiments indicate that LMP2, a constitutively 
tyrosine-phosphorylated integral membrane protein, blocks 
the effects of slg cross-linking at or near the earliest points 
in the BCR signal transduction cascade. Triggering the 
BCR on cells transformed by LMP2 null EBV recombinants 
results in the expected increase in tyrosine phosphoryla- 
tion of Lyn, Syk, PI3-K, PLC72, Vav, Shc, and MAPK, and 
in the specific association of slg complexes with activated 
Lyn and Syk PTKs. In contrast, Lyn PTK from cells trans- 
formed by LMP2 ÷ wild-type EBV is slightly decreased in 
abundance, is substantially decreased in enzymatic activ- 
ity, and is nonresponsive to slg cross-linking. Syk is consti- 
tutively tyrosine phosphorylated in cells transformed by 
wild-type EBV, yet Syk activity is not increased, and Syk 
is nonresponsive to slg cross-linking. Like Syk, PI3-K, 
PLC~,2, and Vav are increased in constitutive tyrosine 
phosphorylation in the absence of increased activity in 
unstimulated EBV+LMP2 + cells, and are unaffected by slg 
stimulation. 
Lyn and other Src family PTKs are activated immediately 
upon slg cross-linking on normal B lymphocytes, and are 
required for phosphorylation of two conserved tyrosines 
within the YXXL(N)~YXXL motif in the cytoplasmic ompo- 
nents of Ig~ and Ig13 (for review see DeFranco, 1993; Weiss 
and Littman, 1994). The reduction in Lyn abundance and 
enzymatic activity in EBV+LMP2 ÷ LCLs is therefore likely 
to be an important factor in the low tyrosine phosphoryla- 
tion of Ige/Igl3 in these cells. Since slg cross-linking only 
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doubles the concentration of components of the BCR com- 
plex, a 50% reduction in Lyn enzymatic activity (as is char- 
acteristic of LMP2 ÷ wild-type EBV-transformed cells) could 
result in loss of the effect of slg cross-linking. In a mutant 
variant of the Jurkat T cell line, a 2-fold reduction in Fyn 
activity results in diminished CD3-mediated tyrosine phos- 
phorylation and insufficient activation of ZAP-70, the T cell 
equivalent of Syk (Tsgankov et al., 1994). 
As expected, the reduced slg complex-associated Syk 
activity following receptor cross-linking of wild-type EBV- 
transformed B lymphocytes was associated with poor 
PLC72 activation. The central role of Syk in slg signal 
transduction is highlighted by studies in a Syk-inactivated 
chicken B cell line, where slg cross-linking did not induce 
tyrosine phosphorylation f PLCy2, and both IP3 and Ca 2+ 
responses were lost (Takata et al., 1994). Wild-type EBV- 
transformed B lymphocytes are functionally similar to Syk- 
deficient chicken B cells, since there is very little slg- 
mediated induction of PLCy2 tyrosine phosphorylation or 
calcium mobilization (Figure 6C; Miller et al., 1994). 
The lack of PTK responses to slg stimulation in EBV ÷- 
LMP2 ÷ LCLs are likely to be linked to the ability of LMP2 
to associate with Src family and Syk PTKs, and to remain 
constitutively aggregated and tyrosine phosphorylated in 
membrane patches (Burkhardt et al., 1992; Figures 1B 
and 5; Longnecker et al., 1991). The Lyn and Syk interac- 
tions map to the N-terminal cytoplasmic domain of LMP2, 
which contains a YEEA and a YXXL(N)TYXXL motif (Long- 
necker et al., 1991; Burkhardt et al., 1992). Constitutively 
clustered membrane patches of tyrosine-phosphorylated 
LMP2 therefore mimic activated slg receptor complexes, 
thereby competing for PTKs, which would otherwise re- 
spond to slg cross-linking. Thus, LMP2 may be a dominant 
negative receptor decoy for Lyn and Syk. Overall Lyn activ- 
ity in EBV÷LMP2 + cells is reduced by approximately 50%, 
whereas Syk activity is only slightly reduced. The subtle 
reduction in Syk activity would only be of significance if 
the reduction is in a functionally important component or 
compartment of the total Syk activity. The difference in 
slg-associated Syk activities in EBV÷LMP2 - versus EBV ÷- 
LMP2 ÷ transformed cells is consistent with this possibility. 
Recent studies have demonstrated that chimeric CD8 
receptors with an LMP2 N-terminal cytoplasmic domain 
can transduce signals in B lymphocytes, supporting the 
idea that the LMP2 N-terminal cytoplasmic domain shares 
structural and functional properties with the cytoplasmic 
sequences of the BCR, TCR, and Fc receptors (Beaufils 
et al., 1993; Alber et al., 1993; Miller et al., 1994). However, 
the conclusions drawn from these studies, that LMP2 may 
function in latent EBV infection to trigger the activation 
and proliferation of infected B lymphocytes, are inconsis- 
tent with extensive recombinant genetic analyses indicat- 
ing that LMP2 is completely dispensable for growth trans- 
formation by EBV (Longnecker et al., 1992, 1993a, 1993b; 
Kim and Yates, 1993). Consistent with the lack of effect 
of LMP2 domains on cell growth is the new data that shows 
no increase in constitutive Shc or MAPK tyrosine phos- 
phorylation in wild-type EBV-transformed LCLs. 
An alternative interpretation of the chimera studies, con- 
sistent with all LM P2 data, is that the constitutive aggrega- 
tion of LMP2 in the plasma membrane, which is mediated 
by the multiple membrane spanning domains, leads to 
constitutive aggregation of LMP2 N-terminal cytoplasmic 
domains. Since tyrosine-phosphoryiated LMP2 N termini 
mimic activated tyrosine-phosphorylated BCR cytoplasmic 
sequences, LMP2 will constitut!vely associate with Lyn 
and Syk, resulting in partial sequestration of these PTKs. 
Equally important, constitutive mimicry of activated slg 
receptoi" complexes by LMP2 appears to result in constitu- 
tive desensitization to authentic slg cross-linking. Consis- 
tent with this is the fact that ligand binding to slgM or slgD 
renders B lymphocytes unable to respond to subsequent 
ligand binding (Cambier et al., 1988). This desensitization 
is long-lived, requires ligation of only a small percentage 
of slg molecules, and does not reflect downmodulation of 
the slg molecules (Cambier et al., 1988; Lazarus et al., 
1990). Therefore, while the N terminus of LMP2 may share 
some structural properties with cytoplasmic signal-trans- 
ducing components of immunological receptors, its in vivo 
functional properties are predicted to be quite different in 
the context of 12 hydrophobic membrane-spanning do- 
mains that are constitutively aggregated in multimeric 
membrane patches. While unnecessary for Lyn and Syk 
association, the multiple transmembrane domains of LMP2 
are critical for the aggregation of LMP2 in the plasma mem- 
brane, and for the effects of LMP2 in blocking receptor- 
mediated signal transduction. In fact, cells transformed 
by LMP2 mutant EBV in which only the cytoplasmic N 
terminus and first five transmembrane domains are ex- 
pressed has an intermediate phenotype in blocking slg- 
induced Ca 2+ mobilization (Miller et al., 1994). 
Viewed in this context, LMP2 may also influence normal 
regulator(s) of Lyn and Syk enzymatic activities. The activi- 
ties of Src family PTKs are negatively regulated by phos- 
phorylation of a C-terminal Tyr residue by Csk PTK, and 
the recently described Ctk PTK (for review see Bolen, 
1993; Cooper and Howell, 1993; Mustelin and Burn, 1993). 
Csk-negative mice display reduced tyrosine phosphoryla- 
tion at the negative regulatory Tyr of Src family PTKs and 
increased tyrosine phosphorylation at the positive regula- 
tory autophosphorylation Tyr; demonstrate increased en- 
zymatic activity of Src-related PTKs; and show embryonic 
lethality (Imamoto and Soriano, 1993; Nada et al., 1993). 
Overexpression of Csk in T lymphocytes negatively regu- 
lates TCR-induced tyrosine protein phosphorylation and 
lymphokine production (Chow et al., 1993). LMP2 expres- 
sion might result in constitutive activation of Csk or a re- 
lated enzyme, thereby preventing slg-stimulated activa- 
tion of Lyn and other Src family PTKs. Reduced baseline 
Lyn activity is consistent with this nterpretation. It is not 
known whether there are negative regulatory tyrosines 
present in Syk. However, the observation that tyrosine- 
phosphorylated Syk is elevated in EBV÷LMP2 ÷ LCLs, with 
slightly decreased enzymatic activity, suggests that Syk 
can be negatively regulated. Current studies are aimed 
at mapping and comparing the sites of tyrosine phosphory- 
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lation of Lyn and Syk in EBV+LMP2 ÷ and EBV÷LMP2 
LCLs. 
As an alternative to Csk or Ctk, a phosphatase is another 
potential target of the negative effects of LM P2. The CD45 
transmembrane protein tyrosine phosphatase is the pre- 
dominant phosphatase on B cell plasma membranes and 
appears to interact physically with slg complexes (Juste- 
ment et al., 1991). CD45- B cells do not signal through slg 
receptor complexes unless CD45 expression is restored. 
Signal transduction through the TCR similarly requires 
CD45 activity (for review see Koretzky, 1993). 
The demonstration that a number of cellular proteins 
have increased phosphorylated tyrosine in EBV+LMP2 ÷ 
LCLs may also be indicative of altered kinase or phospha- 
tase activity. Increased tyrosine phosphorylation of these 
proteins, in the absence of increased enzymatic activities, 
may reflect negative regulatory phosphorylation events. 
LMP2 may recruit these molecules into complexes with 
LMP2-associated Lyn and Syk through interaction with 
one of the eight Tyr residues in the LMP2 N terminus. Upon 
tyrosine phosphorylation, these residues would provide 
eight potential sites for interaction with SH2-containing 
proteins such as Src family PTKs, Syk, PI3-K p85, PLC~'2, 
Vav, and possibly others. Thus, increased tyrosine phos- 
phorylation of these PTK substrates may reflect their prox- 
imity to PTKs, or their protection from phosphatase activ- 
ity, while complexed with tyrosine-phosphorylated LMP2. 
The existence of stable complexes between LMP2 and 
these downstream PTK substrates is currently under in- 
vestigation. 
Unlike Syk, PI3-K, Vav, and PLC~,2, Shc and MAPK are 
not constitutively tyrosine phosphorylated in wild-type EBV- 
transformed LCLs. This suggests that Shc and MAPK are 
not regulated by the same PTKs or phosphatases as Syk, 
PI3-K, Vav, and PLC~,2. The fact that Shc and MAPK are 
not constitutively tyrosine phosphorylated in EBV+LMP2 ÷ 
LCLs is, however, consistent with the fact that LMP2 does 
not affect the growth of EBV-transformed B lymphocytes 
(Longnecker et al., 1992, 1993a, 1993b; Kim and Yates, 
1993). Constitutive activation of the Ras pathway would 
have implicated LMP2 in growth transformation, similar 
to the finding that growth transformation by polyoma virus 
middle T antigen involves the binding and constitutive tyro- 
sine phosphorylation of Shc (Dilworth et al., 1994). 
The ability of LMP2 to downmodulate the cellular conse- 
quences of slg cross-linking on B lymphocyte activation 
and reactivation of lytic EBV infection implicate L.MP2 as 
an important component of EBV persistence in humans. 
These studies have demonstrated that LMP2 is a domi- 
nant negative inhibitor of the slg-associated PTKs, Lyn 
and Syk. Thus, by reducing Lyn abundance and enzymatic 
activity of Lyn and Syk, the tyrosine kinase cascade in 
primary B lymphocytes infected with EBV is not activated 
upon slg cross-linking, preventing the generation of sec- 
ond messengers that would otherwise promote a switch 
to lytic infection. EBV÷LMP2 - and EBV÷LMP2 ÷ LCLs will 
be important in the study of effects of slg-mediated signal 
transduction on the maintenance and disruption of EBV 
latent infection, and may also be useful as a model in whioh 
to study slg receptor desensitization and nonreceptor PTK 
regulation. 
Experimental Procedures 
Cell Lines and Cell Culture 
Ramos is a slgM + Burkitt lymphoma cell line used as a representative 
EBV- human B cell line. Derivation of the EBV*LMP2 and EBV+LMP2 ÷ 
LCLs has previously been described (Longnecker et al., 1993b). In 
brief, normal human B lymphocytes were infected with either w!ld-type 
or LMP2 null mutant recombinant EBV. Established EBV+LMP2 - and 
EBV+LMP2 * LCLs used in this study were similarly slgM+lgD~ as deter- 
mined by fluorescence activated cell sorting analysis with average 
mean fluorescence values ranging between 63-93 as previously deter- 
mined (Miller et al., 1994). All cell lines were maintained in RPM11640 
supplemented with 10% heat-inactivated fetal bovine serum and gen- 
tamicin (2 mg/ml). 
Antibodies 
Goat anti-human immunoglobulin for cross-linking slg experiments 
were purchased from Southern Biotechnical Associates, and rabbit 
anti-human immunoglobulin for im munoprecipitation of immunoglobu- 
lin complexes was purchased from Jackson Immuno Laboratories. 
Rabbit polyclonal anti-LMP2 has been previously described (Long- 
necker et al., 1991). Polyclonal and monoclonal antibodies to Src fam- 
ily kinases, phosphotyrosine, and Ig13 have previously been described 
(Liet al., 1992). Rabbit antibodies to Syk and Btk have recently been 
described (Saouaf et al., 1994; Burkhardt et al., 1994). Rabbit antibod- 
ies to PLC'y1, PI3-K p85, p95 Vav, and Shc antibodies were purchased 
from Upstate Biotechnology, Incorporated. Rabbit antibodiesto PLCy2 
and Grb2 were provided by the laboratories Of S. G. Rhee and M. 
Barbacid, respectively. 
Cellular Activation and Preparation of Lysates 
Tissue culture cells were resuspended jn serum-free RPMI 1640 at 
the cell number/ml indicated in figure legends, and were equilibrated 
at 37°C for 15 min. Anti-human immunoglobulin was added at 25 ~g/ 
ml, and aliquots were removed at timepoints as indicated in the figure 
legends. Cells were immediately l sed in 1 x NP-40 lysis buffer (1% 
Nonidet P-40, 50 mM Tris-HCI [pH 7.4], 150 mM NaCI, 2 mM EDTA, 
10 mg/ml each aprotinin and leupeptin, 0.5 mM phenylmethylsulfonyl 
fluoride, and 1 mM sodium orthovanadate) or1 x digitonin lysis buffer 
(1% digitonin, 10 mM Triethanolamine [pH 7.8], 150 mM NaCI, 1 mM 
EDTA, 10 mg/ml each aprotinin and leupeptin, 0.5 mM PMSF, and 1 
mM sodium orthovanadate) as indicated. Insoluble material was re- 
moved by centrifugation at 4°C, and cleared suPernatants were pro- 
cessed for immunoprecipitations. 
Biochemical Assays 
Immunoprecipitations, immunoblotting, and immune complex kinase 
assays were performed as described (Burkhardt and Bolen, 1993). In 
brief, cleared lysates were incubated on ice for 1 hr with the appropriate 
antisera, and immune complexes were precipitated with Pansorbin 
(Calbiochem), followed by four washes with 1 x lysis buffer. Immuno- 
precipitated proteins were then separated by electrophoresis through 
SDS polyacrylmide gels (percentages are indicated in figure legends). 
For immune complex kinase assays, washed immunoprecipitates 
were further washed in 1 x kinase buffer (20 mM HEPES [pH 7.4], 5 
mM MnCI2), and resuspended in 25 td kinase reaction mix (1 ~Ci/ml 
[~(-32P]ATP in kinase buffer) for the indicated reaction time. To detect 
changes in autophosphorylation potential during anti-immunoglobulin 
time courses, conditions were optimized (cell number, immunoprecipi- 
tating antibody, reaction time) as indicated in the figure legends. The 
reactions were terminated by the addition of 50 i~1 of 2 x reducing 
SDS-PAGE sample buffer. In specific experiments, secondary immu- 
noprecipitations of radiolabeled proteins were carried out after the 
immune complex kinase reaction. For secondary immunoprecipita- 
tions, 125 I~1 of elution buffer (10 mM Tris [pH 7.8], 1% SDS, 1 mM 
sodium orthovanadate) was added to stop the kinase reaction, reac- 
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tions were heated to 95°C for 5 min, and cleared supernatants were 
then diluted 10-fold in 1 x lysis buffer, and reimmunoprecipitated. Sol- 
uble radiolabeled proteins were reimmunoprecipitated as indicated, 
washed, and separated by SDS-PAGE gels. Incorporation of 32p into 
endogenous proteins was visualized by autoradiography. Quantitation 
of phosphorylated reaction products was performed by analysis with 
a Molecular Dynamics Phosphorimager using ImageQuant software. 
For immunoblotting, immune complex material was electropho- 
rased and transferred to nitrocellulose. Filters were blocked in 5% 
bovine Serum albumin (Calbiochem) in phosphate buffered saline 
(PBS) for 1 hr at room temperature. Primary antibodies were diluted 
in 1% bovine serum albumin PBS, and filters were incubated in primary 
antibody for 1 hr at room temperature. Filters were washed three times 
in PBS, 10 min each wash, and incubated with 50 i~Ci of '2si protein 
A diluted in 1% bovine serum albumin PBS for 40 min. Filters were 
washed three times in PBS, 10 rain each wash, and subjected to auto- 
radiography. 
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